Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia September 28, 2022 — Preliminary data from the ongoing Phase 1b study shows RLYB212 rapidly and completely eliminates transfused HPA-1a positive platelets. — Proof-of-Concept Data Expected in 1Q 2023. Read the full news ...
‘He’s never alone’ Dad has his head tattooed to honour his son’s brain surgery. Carlos Marquez, from North Bergen, New Jersey, USA wanted to get a tattoo to honor his son Luke, 1, who has hydrocephalus due to FNAIT and needed a shunt to drain the excess fluid that builds up in his ...
Cambridge Rare Disease Network Festival #RAREfest22 – 25th-26th November 2022 RAREfest22 has patients at its heart with science and technology running through its veins! Cambridge Rare Disease Network’s festival is back in person showcasing expert speakers, live podcasts, panel discussions hands-on exhibits and film from the world of science, tech, and advocacy. Join us ...
Today our lovely team completed the Challenge raising £1,473.16!! Read more about the team and Alan’s son Theo 8 here Thank you to everyone involved!!!
September 2021 New rules mean if you live in England your can now DONATE PLASMA!! Plasma is needed to make immunoglobulin medicine that can be used to treat many conditions, saving many lives…. THANK YOU!!! Your plasma will help people with cancers, rare diseases, immune disorders and genetic conditions. Register online or call ...
Rallybio Announces First-in-Human Dosing in RLYB211 Phase 1/2 Study. RLYB211 is in Clinical Development for the Prevention of FNAIT, a Potentially Life-Threatening Rare Disorder that Impacts Fetuses and Newborns. NEW HAVEN, Conn., November 10, 2020. Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and ...
